[{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"177-Lu NeoB","moa":"||GRPr","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Entinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase III","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Syndax Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Syndax Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ahon Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Anastrozole","moa":"||CDK4 \/ CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Ahon Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ahon Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ahon Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jules Bordet Institute","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Entrectinib","moa":"||Proto-oncogene tyrosine-protein kinase ROS | Neurotrophic tyrosine kinase receptor | ALK tyrosine kinase receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Jules Bordet Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jules Bordet Institute \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Jules Bordet Institute \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alpelisib","moa":"||PI3-kinase p110-alpha subunit","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"Novartis Pharmaceuticals Corporation | Vestre Viken Hospital Trust","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Letrozole","moa":"||Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akershus University Hospital \/ Novartis Pharmaceuticals Corporation | Vestre Viken Hospital Trust","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ Novartis Pharmaceuticals Corporation | Vestre Viken Hospital Trust"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Zenith Epigenetics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Goserelin","moa":"||BET","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Zenith Epigenetics | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Zenith Epigenetics | National Cancer Institute"},{"orgOrder":0,"company":"Yale University","sponsor":"Novartis Pharmaceuticals Corporation | Breast Cancer Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Yale University \/ Novartis Pharmaceuticals Corporation | Breast Cancer Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Novartis Pharmaceuticals Corporation | Breast Cancer Research Foundation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||CDK4\/6","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Praful Ravi, MB BCHir, MRCP","sponsor":"Eli Lilly | Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Praful Ravi, MB BCHir, MRCP","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Praful Ravi, MB BCHir, MRCP \/ Eli Lilly | Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"Praful Ravi, MB BCHir, MRCP \/ Eli Lilly | Bayer AG"},{"orgOrder":0,"company":"TerSera Canada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"||Undisclosed","graph1":"Oncology","graph2":"Approved FDF","graph3":"TerSera Canada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"TerSera Canada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TerSera Canada \/ Inapplicable"},{"orgOrder":0,"company":"Ahon Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"FCN-437c","moa":"||CDK4 \/ CDK6","graph1":"Oncology","graph2":"Phase III","graph3":"Ahon Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ahon Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ahon Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Apalutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"ECOG-ACRIN Cancer Research Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"HPAPI","year":"2020","type":"Inapplicable","leadProduct":"Darolutamide","moa":"||Androgen Receptor","graph1":"Oncology","graph2":"Phase III","graph3":"ECOG-ACRIN Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"ECOG-ACRIN Cancer Research Group \/ National Cancer Institute"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Panbela Therapeutics | Prostate Cancer Foundation | US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||ODC","graph1":"Oncology","graph2":"Phase II","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Panbela Therapeutics | Prostate Cancer Foundation | US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Panbela Therapeutics | Prostate Cancer Foundation | US Department of Defense"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"Ministry of Health and Welfare | Debiopharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Taiwan University Hospital \/ Ministry of Health and Welfare | Debiopharm","highestDevelopmentStatusID":"8","companyTruncated":"National Taiwan University Hospital \/ Ministry of Health and Welfare | Debiopharm"},{"orgOrder":0,"company":"Radboud University Medical Center","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Radboud University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Radboud University Medical Center \/ ZonMw","highestDevelopmentStatusID":"8","companyTruncated":"Radboud University Medical Center \/ ZonMw"},{"orgOrder":0,"company":"Peptigroupe","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Peptigroupe","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Peptigroupe \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Peptigroupe \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Varian Medical Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"||Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Undisclosed","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ Varian Medical Systems","highestDevelopmentStatusID":"1","companyTruncated":"Washington University School of Medicine \/ Varian Medical Systems"}]

Find Clinical Drug Pipeline Developments & Deals for Goserelin Acetate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Amcenestrant,Palbociclib,Goserelin Acetate

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 20, 2020

                          Lead Product(s) : Amcenestrant,Palbociclib,Goserelin Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          Yale University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Yale University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 01, 2025

                          Lead Product(s) : Ribociclib,Letrozole,Anastrozole,Goserelin Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Novartis Pharmaceuticals Corporation | Breast Cancer Research Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                          Country arrow
                          EPSC
                          Not Confirmed

                          Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 10, 2025

                          Lead Product(s) : ZEN-3694,Testosterone Cypionate,Goserelin Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Zenith Epigenetics | National Cancer Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Health Canada has approved a sNDA for ZOLADEX LA (goserelin acetate), GnRH agonist at 10.8mg every 12 weeks for the management of ER+ early breast cancer in pre- and perimenopausal women.

                          Product Name : Zoladex

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          July 05, 2024

                          Lead Product(s) : Goserelin Acetate,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          National Taiwan University Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          National Taiwan University Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          January 25, 2024

                          Lead Product(s) : Goserelin Acetate,Leuprolide Acetate,Triptorelin Pamoate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Ministry of Health and Welfare | Debiopharm

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                          Country arrow
                          EPSC
                          Not Confirmed

                          Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 28, 2023

                          Lead Product(s) : Eflornithine Hydrochloride,Testosterone Cypionate,Goserelin Acetate,Enzalutamide

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Panbela Therapeutics | Prostate Cancer Foundation | US Department of Defense

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Inapplicable

                          May 23, 2023

                          Lead Product(s) : 68-Ga NeoB,177-Lu NeoB,Ribociclib,Fulvestrant,Goserelin Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          May 12, 2023

                          Lead Product(s) : Goserelin Acetate,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 24, 2023

                          Lead Product(s) : Ribociclib,Letrozole,Anastrozole,Goserelin Acetate,Leuprolide Acetate,Exemestane

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed